Hypertension Updates Every Pharmacist Should Know

Advancements in hypertension management are shifting the landscape of treatment, from new guideline recommendations to technological innovations. This course explores key highlights from the AHA's recent scientific statements, including single-pill combination therapy and the clinical limitations of some blood pressure devices, alongside updates to the 2025 hypertension guidelines. You will gain a clear understanding of how these changes affect patient care, medication strategies, and pharmacist-driven interventions.Recent ACC/AHA Cholesterol Guidelines further emphasize comprehensive cardiovascular risk assessment and evidence-based management of dyslipidemia alongside other major risk factors such as hypertension. These updates complement the hypertension topics discussed in this episode by reinforcing the importance of coordinated, risk-based approaches to reducing cardiovascular disease.This resource provides a concise, guideline-based overview of hypertension management, summarizing the 2025 ACC/AHA recommendations for blood pressure classification, treatment goals, and stepwise pharmacotherapy. It highlights first- and second-line antihypertensive options, emphasizes individualized, risk-based treatment decisions, and outlines practical considerations for therapy initiation, intensification, and monitoring to optimize cardiovascular outcomes.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTTomasz Jurga,  PharmD, BCPS, BCACP, BCCP, HF-Cert, CDCES, AACCClinical Pharmacist PractitionerLTC Charles S. Kettles VA Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify recent guideline and practice updates that may influence the diagnosis, treatment, and monitoring of hypertension.2. Discuss current and emerging tools Follow CEimpact on Social Media:LinkedInInstagram

Alpha-gal syndrome (AGS), a growing allergy linked to tick bites and mammalian meat exposure, is a condition pharmacists can’t afford to overlook. This course discusses the pathophysiology of the syndrome, common triggers, and emerging case trends—while highlighting how pharmacists can play a critical role in helping patients navigate safe OTC and prescription therapies by screening for allergenic excipients. You will gain practical knowledge to support patient education, ensure safe medication use, and guide appropriate referrals.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTGeoff Wall, PharmD, BCPSProfessor of Pharmacy PracticeDrake UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the pathophysiology, triggers, and clinical presentation of alpha‑gal syndrome.2. Identify pharmacist‑led strategies for patient counseling, medication review, and referral when AGS is suspected or confirmed.Rachel Maynard and Geoff Wall have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-058-H01-PInitial release date: 3/30/2026Expiration date: 3/30/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Artificial intelligence (AI) is rapidly transforming the healthcare landscape—and pharmacy is no exception. This course explores emerging and potential uses of AI in pharmacy practice, including workflow automation, drug information access, and tools that support patient care and clinical decision-making. You will gain insight into practical considerations, limitations, and ethical responsibilities pharmacists must navigate as AI becomes more integrated into practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTTimothy Aungst, PharmDProfessor of Pharmacy PracticeMassachusetts College of Pharmacy and Health SciencesGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify current and potential uses of AI that support pharmacist-led patient care services.2. Describe considerations, limitations, and ethical concerns related to implementing AI tools in pharmacy practice.Rachel Maynard and Timothy Aungst have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-060-H04-PInitial release date: 3/23/2026Expiration date: 3/23/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSarah Grady, PharmD, BCPS, BCPPProfessor of Pharmacy Practice, Clinical PharmacistDrake University/Broadlawns Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-059-H01-PInitial release date: 3/16/2026Expiration date: 3/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.  PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-081-H01-PInitial release date: 3/9/2026Expiration date: 3/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent changes to childhood vaccine recommendations have introduced shared clinical decision‑making for several immunizations that were previously universally recommended, creating confusion among patients and providers alike. This course explains what shared clinical decision‑making means in the context of immunizations, examines how it affects pediatric vaccine discussions, and highlights opportunities for pharmacists to support informed, individualized conversations with patients and caregivers. You will gain clarity on how to apply shared clinical decision‑making principles—alongside proven health coaching strategies—to strengthen patient trust and foster more meaningful dialogue in pharmacy practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTElizabeth Skoy, PharmD, RPhProfessorNorth Dakota State UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe shared clinical decision-making and how it applies to recent pediatric vaccine recommendations.2. Identify the pharmacist's roles in counseling, education, and facilitating shared clinical decision-making conversations with patients and caregivers. Rachel Maynard and Elizabeth Skoy have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-077-H01-PInitial release date: 3/2/2026Expiration date: 3/2/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

As gabapentin climbs the ranks to become one of the most prescribed medications in the U.S., questions about its safety and scope of use are also rising. This episode explores recent trends in gabapentin use, highlights key patient safety concerns, and examines pharmacist-led opportunities to reduce risks through education and medication review. You will walk away with timely insights to help navigate the growing complexities and responsibilities associated with gabapentin use.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTNakia Duncan, PharmD BCGP, BCPSAssociate Professor/ Pain& Palliative Care Clinical PharmacistTexas Tech Health Science Center - School of PharmacyGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent national prescribing trends and safety concerns associated with gabapentin use.2. Identify pharmacist-led strategies to support safe use, patient education, and medication review involvinggabapentin.Rachel Maynard and Nakia Duncan have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-053-H01-PInitial release date: 2/23/2026Expiration date: 2/23/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent updates to U.S. guidelines for HIV post‑exposure prophylaxis (PEP) provide modernized recommendations for both non‑occupational and occupational exposures — reflecting advances in antiretroviral therapy and evolving evidence. This course summarizes key changes, including preferred regimens, testing/follow‑up modifications, and special‑population considerations, and explores how these updates influence clinical practice. You will gain the practical knowledge needed to inform prompt PEP decision‑making, patient counseling, and care coordination.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTKenric Ware, Pharm D Clinical Associate Professor of Pharmacy PracticeMercer UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify current guideline recommendations for initiating HIV PEP after occupational and non-occupational exposure.2. Describe key considerations for selecting and managing HIV PEP regimens.Rachel Maynard and Kenric Ware have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-052-H01-PInitial release date: 2/16/2026Expiration date: 2/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent developments in HIV prevention — including the FDA approval of a 6‑month injectable option and updated clinical guidance — are changing the landscape of Pre-Exposure Prophylaxis (PrEP) therapy. This course reviews the latest developments, compares prevention strategies, and examines how these changes affect PrEP delivery, counseling, and monitoring. You will gain timely insights to better counsel patients, support adherence, and contribute to prevention strategies in your practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTDavid Hachey, PharmD, AAHIVP Professor Idaho State University GET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe key new HIV PrEP therapy options recently approved or recommended, including their dosing schedules and clinical indications.2. Identify pharmacist responsibilities when counseling patients about PrEP, including initiation, adherence, monitoring, and risk-benefit discussions. Rachel Maynard and David Hachey have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-049-H01-PInitial release date: 2/9/2026Expiration date: 2/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTReemal Zaheer, PharmD, CSPPharmacistJohns Hopkins MedicineGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of biosimilars in the treatment of inflammatory conditions.2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies.Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 HrUAN: 0107-0000-26-045-H01-PInitial release date: 2/2/2026Expiration date: 2/2/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram